What's in Sun Pharmaceutical Industries Limited's pipeline?

Sun Pharmaceutical Industries Limited has 34 drugs in our index: 5 marketed, 0 filed, 9 in Phase 3, 19 in Phase 2, 1 in Phase 1.

Which companies overlap with Sun Pharmaceutical Industries Limited's portfolio?

Top competitors by shared drug class: Beijing Tiantan Hospital, EMS, Astellas Pharma Inc, AstraZeneca, Beni-Suef University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sun-pharmaceutical-industries-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sun Pharmaceutical Industries Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sun Pharmaceutical Industries Limited pipeline: 5 marketed, 0 filed, 9 Phase 3, 19 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 9 Phase 3 19 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bromday™	Bromday™	marketed
TILD	TILD	marketed		Interleukin-23	Immunology
Halobetasol Topical Lotion	Halobetasol Topical Lotion	marketed	Topical corticosteroid (Class I, super-potent)	Glucocorticoid receptor	Dermatology
SAPHRIS	SAPHRIS	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor	Psychiatry
Injections of tildrakizumab	Injections of tildrakizumab	marketed	IL-23 inhibitor monoclonal antibody	IL-23 (interleukin-23), p19 subunit	Immunology/Dermatology
ISV-305	ISV-305	phase 3			Oncology
SPIL1033	SPIL1033	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
OTX-101 0.09%	OTX-101 0.09%	phase 3	ophthalmic solution		Ophthalmology
Zero-dose	Zero-dose	phase 3			Infectious Diseases
matching placebo injections	matching placebo injections	phase 3
vehicle of OTX-101	vehicle of OTX-101	phase 3
PART 1: Double-blind Placebo-controlled	PART 1: Double-blind Placebo-controlled	phase 3	SSRI	Serotonin transporter	Psychiatry

Therapeutic area mix

Oncology · 2
Ophthalmology · 2
Psychiatry · 2
Immunology/Dermatology · 1
Dermatology · 1
Infectious Diseases · 1
Diabetes · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Beijing Tiantan Hospital · 2 shared drug classes
EMS · 2 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Beni-Suef University · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sun Pharmaceutical Industries Limited:

Cite this brief

Drug Landscape (2026). Sun Pharmaceutical Industries Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sun-pharmaceutical-industries-limited. Accessed 2026-05-17.